Generate Biomedicines and Zealand Pharma agree AI-designed obesity protein deal

Generate Biomedicines/GB-0895 (anti-TSLP)

Generate Biomedicines and Zealand Pharma will develop multispecific protein therapies for obesity and other metabolic diseases, using Generate's AI platform. Generate leads research through candidate selection; Zealand takes over clinical development, regulatory submissions and worldwide commercialisation.

• Generate receives $30 million upfront and is eligible for up to $35 million in early preclinical milestones.
• Total milestone payments are described as nearly $1.2 billion.
• Multispecific therapies act on more than one biological target at once, so one medicine could address several obesity-linked pathways.
• No specific program or target is named in the announcement.